Key Takeaways
- • CVC and Groupe Bruxelles Lambert (GBL) increased their takeover bid for Italian pharmaceutical company Recordati to €53.71 per share, up from €51.29 per share, on October 6, 2026.
- • The revised offer represents the investors' "best and final offer" as they seek to take Recordati private.
- • The bid increase signals intensified pursuit of the acquisition, with the higher per-share price designed to secure shareholder approval for the going-private transaction.
Summary
CVC Capital Partners and Groupe Bruxelles Lambert announced an increased takeover offer for Recordati, the Italian pharmaceutical company, raising their per-share bid to €53.71 from the previous €51.29 level. The move, disclosed on October 6, 2026, positions the offer as the investors' final proposal in their effort to acquire the company and take it private.
The elevated bid reflects a strategic escalation in the acquisition process, with the consortium signaling its commitment to completing the transaction. By framing the new offer as "best and final," CVC and GBL indicated their willingness to significantly improve terms while establishing a ceiling for negotiations, a standard tactic in leveraged buyout contests designed to reduce uncertainty and facilitate board and shareholder acceptance.
The transaction represents a significant development in pharmaceutical sector M&A activity and underscores the continued appetite among large alternative asset managers for acquiring profitable, established healthcare businesses with predictable cash flows and market positions.
The elevated bid reflects a strategic escalation in the acquisition process, with the consortium signaling its commitment to completing the transaction. By framing the new offer as "best and final," CVC and GBL indicated their willingness to significantly improve terms while establishing a ceiling for negotiations, a standard tactic in leveraged buyout contests designed to reduce uncertainty and facilitate board and shareholder acceptance.
The transaction represents a significant development in pharmaceutical sector M&A activity and underscores the continued appetite among large alternative asset managers for acquiring profitable, established healthcare businesses with predictable cash flows and market positions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.